EAM
Eventide Asset Management Portfolio holdings
AUM
$5.71B
This Quarter Return
+2.79%
1 Year Return
+51.18%
3 Year Return
+209.28%
5 Year Return
+283.63%
10 Year Return
+1,480.39%
AUM
$5.84B
AUM Growth
+$5.84B
(-8.4%)
Cap. Flow
-$173M
Cap. Flow
% of AUM
-2.96%
Top 10 Holdings %
Top 10 Hldgs %
25.28%
Holding
174
New
17
Increased
89
Reduced
33
Closed
14
Top Buys
| 1 |
Axsome Therapeutics
AXSM
|
$47.7M |
| 2 |
Nextracker
NXT
|
$36.6M |
| 3 |
Nutanix
NTNX
|
$34.1M |
| 4 |
Quanta Services
PWR
|
$32M |
| 5 |
Geron
GERN
|
$27M |
Top Sells
| 1 |
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
|
$165M |
| 2 |
Coursera
COUR
|
$63.3M |
| 3 |
Sprout Social
SPT
|
$57.1M |
| 4 |
dLocal
DLO
|
$49.4M |
| 5 |
Global E Online
GLBE
|
$45.9M |
Sector Composition
| 1 | Healthcare | 37.83% |
| 2 | Technology | 25.34% |
| 3 | Industrials | 17.52% |
| 4 | Consumer Discretionary | 8.37% |
| 5 | Communication Services | 2.18% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Krystal Biotech
KRYS
$4.36B
| $25.1M | 0.43% |
136,485
| – | – |
|
|
BPMC
77
DELISTED
Blueprint Medicines
BPMC
| $25M | 0.43% |
231,685
| – | – |
|
78
AvalonBay Communities
AVB
$27B
| $24.7M | 0.42% |
+119,178
| New | +$24.7M |
|
79
Pentair
PNR
$17.5B
| $24.4M | 0.42% |
318,119
+1,321
| +0.4% | +$101K |
|
80
NetApp
NTAP
$23.2B
| $23.7M | 0.41% |
184,256
+78,752
| +75% | +$10.1M |
|
81
Verisk Analytics
VRSK
$37.2B
| $22.9M | 0.39% |
85,138
+26,084
| +44% | +$7.03M |
|
82
Keros Therapeutics
KROS
$651M
| $22.8M | 0.39% |
499,208
-180,792
| -27% | -$8.26M |
|
83
Southern Company
SO
$100B
| $22.6M | 0.39% |
291,413
+122,550
| +73% | +$9.51M |
|
84
Biohaven
BHVN
$1.78B
| $22M | 0.38% |
634,664
+233,563
| +58% | +$8.11M |
|
85
Element Solutions
ESI
$6.13B
| $21.8M | 0.37% |
802,113
+64,198
| +9% | +$1.74M |
|
86
Workday
WDAY
$62.2B
| $21.6M | 0.37% |
96,787
+2,236
| +2% | +$500K |
|
87
United Therapeutics
UTHR
$18.4B
| $21.6M | 0.37% |
+67,825
| New | +$21.6M |
|
88
Alnylam Pharmaceuticals
ALNY
$59.3B
| $21.1M | 0.36% |
87,000
| – | – |
|
89
Public Service Enterprise Group
PEG
$40.6B
| $21.1M | 0.36% |
286,296
+54,621
| +24% | +$4.03M |
|
90
Novanta
NOVT
$4.03B
| $20.6M | 0.35% |
126,404
+45
| +0% | +$7.34K |
|
|
CERE
91
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $20M | 0.34% |
490,000
| – | – |
|
92
Royalty Pharma
RPRX
$15.8B
| $19.8M | 0.34% |
749,630
+58,943
| +9% | +$1.55M |
|
93
Mobileye
MBLY
$11.3B
| $18.9M | 0.32% |
673,406
+42,027
| +7% | +$1.18M |
|
94
4D Molecular Therapeutics
FDMT
$292M
| $18.5M | 0.32% |
881,157
+105,043
| +14% | +$2.2M |
|
95
BridgeBio Pharma
BBIO
$10B
| $18.2M | 0.31% |
716,927
| – | – |
|
96
Korro Bio
KRRO
$208M
| $17.9M | 0.31% |
529,155
-8,335
| -2% | -$282K |
|
97
Aptiv
APTV
$17.4B
| $17.7M | 0.3% |
250,781
+106
| +0% | +$7.47K |
|
|
INZY
98
DELISTED
Inozyme Pharma
INZY
| $17.6M | 0.3% |
3,936,220
+756,383
| +24% | +$3.37M |
|
|
RCM
99
DELISTED
R1 RCM Inc. Common Stock
RCM
| $17.3M | 0.3% |
1,375,980
| – | – |
|
100
Dyne Therapeutics
DYN
$1.97B
| $17.1M | 0.29% |
+485,000
| New | +$17.1M |
|